Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Table 4 Characteristics of patients in remission (n = 21)

Characteristic
Time to Remission (weeks)
Mean (SD)	21.1 (12.7)
Median	24
Range	4, 34
Time in Absolute Sustained Remission (weeks)^a
Mean (SD)	22.5 (7.5)
Median	25
Range	6, 30
Dose at Remission^b
20 mg, n (%)	5 (23.8)
30 mg, n (%)	2 (9.5)
35 mg, n (%)	4 (19.0)
40 mg, n (%)	2 (9.5)
50 mg, n (%)	8 (38.1)
Dose at the 32-week visit (prior to tapering)
20 mg, n (%)	5 (23.8)
30 mg, n (%)	3 (14.3)
35 mg, n (%)	4 (19.0)
40 mg, n (%)	1 (4.8)
50 mg, n (%)	8 (38.1)
Dose whilst in remission, mg^c
Mean (SD)	30.7 (11.0)
Median	30
Range	10, 50

^a Dose at remission is taken as the dose at first achieving absolute sustained remission for patients achieving absolute sustained remission, and the dose at the 32-week visit for those patients not achieving absolute sustained remission.
^b Time in absolute sustained remission is taken as the difference between the 34-week visit and the week of first achieving absolute sustained remission for patients achieving absolute sustained remission, and as 0 weeks for patients not achieving absolute sustained remission.
^c The dose of all episodes of remission i.e. a MADRS score of ≤8

ISSN: 1471-244X